CLAZAKIZUMAB (CLZ, ANTI-IL-6) AND TOCILIZUMAB (TCZ, ANTI-IL-6 RECEPTOR) DIFFERENTIALLY AFFECT IL-6/IL-6R SIGNALING BY MODULATING SOLUBLE IL-6R & GP130 IN PATIENTS TREATED FOR CHRONIC ANTIBODY-MEDIATED REJECTION (CABMR)

被引：0
|
作者：
Shin, Bongha [1 ]
Vo, Ashley [1 ]
Ge, Shili [1 ]
Petrosyan, Anna [1 ]
Ammerman, Noriko [1 ]
Jordan, Stanley [1 ]
Toyoda, Mieko [1 ]
机构：
[1] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
来源：
TRANSPLANT INTERNATIONAL | 2019年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
LBP023
引用
收藏
页码：410 / 410
页数：1
相关论文
共 50 条
  • [1] Clazakizumab (CLZ, Anti-IL-6 Antibody) and Tocilizumab (TCZ, Anti-IL-6 Receptor [r] Antibody) Treatments Differentially Affect IL-6/IL-6R Signaling by Modulating Soluble IL-6R (sIL-6R) and gp130 (sgp130) in Kidney Transplant Patients (KTx Pts) Treated for Chronic Antibody-Mediated Rejection (cABMR).
    Shin, B.
    Ge, S.
    Petrosyan, A.
    Ammerman, N. F.
    Vo, A. A.
    Jordan, S. C.
    Toyoda, M.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2019, 19 : 452 - 452
  • [2] Clazakizumab (clz, Anti-il-6 Antibody) Treatment Affects Il-6/il-6r Signaling by Increasing Soluble Gp130 (sgp130) in Hla-sensitized Kidney Transplant Patients (hs Ktx Pts) Treated for Chronic Antibody-mediated Rejection (cabmr)
    Shin, B.
    Ge, S.
    Jimenez, A.
    Ammerman, N.
    Vo, A.
    Zhang, R.
    Jordan, S. C.
    Toyoda, M.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2021, 21 : 737 - 738
  • [3] Discovery and characterization of a monoclonal antibody taroeting a conformational epitope of IL-6/IL-6Rα to inhibit IL-6/IL-6Rα/gp130 hexameric signaling complex formation
    Chou, Chun-Chi
    Hua, Kuo-Tai
    Chen, Min-Wei
    Wu, Chin-Jui
    Hsu, Chun-Hua
    Wang, Jann-Tay
    Hsiao, Michael
    Wei, Lin-Hung
    MABS, 2022, 14 (01)
  • [4] Characterization of HZ0412a, a novel potent humanized anti-IL-6 receptor antibody that blocks IL-6R binding to gp130
    Han, Jianzhong
    Liu, Xiaolei
    Xu, Yue
    Wang, Qian
    Li, Li
    Du, Kehe
    Li, Chenchen
    Liu, Hongjun
    Chen, Yu
    Huang, Jian
    ANTIBODY THERAPEUTICS, 2023, 6 (02) : 119 - 126
  • [5] Anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Rejection - Molecular Rebound Phenomena Under IL-6 Blockade?
    Borski, A.
    Haindl, S.
    Duerr, M.
    Budde, K.
    Schranz, S.
    Eskandary, F. A.
    Doberer, K.
    Halloran, P. F.
    Chong, E.
    Jilma, B.
    Boehmig, G. A.
    Wahrmann, M.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2020, 20 : 853 - 853
  • [6] SOLUBLE FORM OF GP130 MOLECULE, AN IL-6 INHIBITOR, CONTRIBUTES THE EFFICACY ON RA TO TOCILIZUMAB (AN ANTI-IL-6 RECEPTOR ANTIBODY) THERAPY
    Yoshizaki, K.
    Song, S. N. J.
    Itoh, H.
    Iwahashi, M.
    Uno, K.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 716 - 716
  • [7] ANTI-IL-6 ANTIBODY CLAZAKIZUMAB IN LATE ANTIBODY-MEDIATED REJECTION - MOLECULAR REBOUND PHENOMENA UNDER IL-6 BLOCKADE?
    Borski, Anita
    Haindl, Susanne
    Durr, Michael
    Budde, Klemens
    Schranz, Sabine
    Eskandary, Farsad A.
    Doberer, Konstantin
    Halloran, Philip F.
    Chong, Edward
    Jilma, Bernd
    Bohmig, Georg A.
    Wahrmann, Markus
    TRANSPLANTATION, 2020, 104 (09) : S67 - S67
  • [8] STUDY ON THE ROLE OF IL-6/IL-6R/GP130 SIGNAL TRANSDUCTION PATHWAY IN NEUROIMMUNOMODULATION
    Zheng, Shuangyan
    Zeng, Chunrong
    Liu, Menglan
    Xiang, Panyi
    Wang, Lin
    Li, Zuoxiao
    ACTA MEDICA MEDITERRANEA, 2021, 37 (04): : 2267 - 2271
  • [9] Alterations of IL-6, IL-6R and gp130 in early and late onset severe preeclampsia
    Zhang, Zhan
    Gao, Yan
    Zhang, Linlin
    Jia, Liting
    Wang, Peng
    Zhang, Lin
    Li, He
    HYPERTENSION IN PREGNANCY, 2013, 32 (03) : 270 - 280
  • [10] Influence of humanized anti-IL-6R antibody, tocilizumab on the activity of soluble gp130, natural inhibitor of IL-6 signaling
    Hashizume, Misato
    Mihara, Masahiko
    RHEUMATOLOGY INTERNATIONAL, 2009, 29 (04) : 397 - 401
12345